Although localized laryn gotracheobronchial amy loidosis is rare, the otolaryngologist-head and neck surgeon should be fam iliar with this condition. Its characteristic appearance can suggest its presence in a patient who has the typica l initia l symptoms. Biopsie s during direct laryngoscopy and bronc hoscopy can play both a diagnostic and therapeutic role. After an appropriate examination to rule out systemic involvement. the patient should be managed with conservative surgery, although the use ofa co2 laser might be more efficac ious than conventional surgery. With appropriate diagn osis and treatmen t, patients should expect afavorable prognosis. In this article. we describe a new case of localized laryngotracheobronchial amyloidosis in a 67-year-old woman. and we review the literature on this subject. 632 upper or lower respiratory tract. A rev iew of the world literature over the past 100 years iden tified a total of 29 previously repor ted cases (table I) .1-8We have reviewed these cases and we present our conclusions regarding the initial symptoms, diagnosis, and management of this unusual disorder.
Introduction
Localized idiopathic amyloidosis of the respiratory tract is rare. It manife sts clin ically either in the upper respiratory tract (usually in the suprag lottic larynx) or in the lower respirator y tract (usually with tracheobronchi al involvement) . The occurrence of localized amyloidosis that involves both the upper and lower respiratory tracts is very unu sual.
We describe a new case of localized laryngotracheobronchial amy loidosis . To date, the literature contains only a few scattered case reports and a few cases mentioned in reviews of amyloido sis loca lized to either the The y can be oral cancer. ( • Laboratory Will automaticall y detect an inadequate specimen so that It cannot result10 test error Repeat specimens areanalyzed at no charge.
• • Nationwideclinical trial performed at thirty-five academic centers by leading specialists 10 oral pathology. oral medicine. and oral surgery. Publ ishedin JADA. October. 1999 .
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Getting Started
The test kit comes with everything you need to perform the brush biopsy. 
Site prior to brush biopsy
Call 1-877-0RALSCAN for your Introductory Package.
Package includes instructions and 4 test kits.
Site after brush biopsy
Preparing the Specimen
Spread the cellular sample from the brush onto the glass slide. Rotate and drag the brush lengthwise, transferring as much material as possible.
Fixative
Quickly squeeze the entire contents of one fixative package onto the glass slide, flooding the slide. Set the slide aside to dry for 15 minutes, then place it in the slide holder.
After completing the test requisition form, you are ready to send the specimen to OralScan Laboratories in the postage-paid box provided.
Results
Surgeons are faxed an OralCDx report usually within 3 days after the specimen is received by the laboratory. For lesions with "positive" or "atypical" OralCDx results, a summary screen containing representative cellular abnormalities is printed (pictured left), and together with a pathologist's explanatory report, is mailed to the surgeon . These images enable the surgeon to explain the abnormal test results to the patient, and substantiate the need for further evaluation of the lesion. Q. Why Is the surgeon's procedure "fail-safe"? A. Each specimen arriving at OralScan Laboratories is automatically evaluated by both the computer system and the specialty pathologist to determine thatthebiopsy brush has penetrated to the basement membrane. This is achieved byverification that cells from all three layers of the epithelium have been obtained. This key feature makes thebrush biopsy procedure "confirmable" or "fail-safe" in thatit assures the surgeon that a complete, full-thickness, transepithelial biopsy specimen has been obtained. In those infrequent instances when the sample obtained bythe surgeon is nota full-thickness, transepithelial biopsy (Which may occur, for example, if insufficient pressure is applied or if the brush is notrotated a sufficient number of times), this cannot result in test error. Instead the surgeon will be informed that the sample was inadequate for analysis.
The brush biopsy should then be repeated at no charge to thepatient. The laboratory also does not charge for analysis of such repeat specimens.
Q. How Is the brush biopsy sample analyzed?
A. In addition to the pathologist's manual microscopic analysis, each brush biopsy specimen is scanned by theOralCOx computer. This consists of a neural-network-based, image-processing system, specifically designed to detect oral epithelial precancerous and cancerous cells. The core technology behind the OralCDx computer was originally developed for the SOl missile defense system. It searches the brush biopsy specimen for a combination of abnormal cellular morphology, abnormal keratinization and DNA ploidy, which uniquely characterizes dysplasia and carcinoma of theoral epithelium. This image analysis process is performed utilizing a specially designed image processor thathas been demonstrated to detect asfew astwo abnormal oral epithelial cells scattered among more than one hundred thousand normal cells typically distributed on each oral brush biopsy specimen.
Q. What does the OralCOx test cost the patient?
A. The patient incurs two fees , one for the brush biopsy procedure and the second for the laboratory analysis of the specimen.
The first charge the patient incurs is the surgeon's fee for performing the brush biopsy procedure. Insurance, including Medicare, will typically reimburse for the biopsy procedure. CPT codes available to report this procedure are supplied with the OralCOx kits.
The second charge the patient incurs is for laboratory analysis of the brush biopsy. OralScan Laboratories will file a claim with the patient's insurance for its laboratory analysis fee. Like thebrush biopsy procedure, this fee is also typically reimbursed by insurance including Medicare.
Q. How can I get test kits?
A. Call Toll-Free 1-877-0RALSCAN (1-877-672-5722) or email to oralcdx@oralscan.com for an introductory package which contains4 test kits.
Note: All of the lesions pictured on the first page were determined to be either precancer or cancer. --------- mucosa-covered mass with a submucosal yellowish waxy appearance in the left anterior subglottis (figure 1). The mass had caused a 30% stenosis at the level of the subglottis. Two similar but smaller lesions were identified in the cervical trachea, and the right lower lobe bronchus was partially occluded by yet another simil arly appearing lesion . Multiple biopsies were taken without complication. A review of pathology confirmed the diagnosis of amyloidosis (figure 2). Specific immunohistochemical staining for the AL subtyp e of amyloid protein was found in the deposits. Three years later, the patient has remained stable and has required no further hospitalization or broncho scopic procedures.
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Discussion
The term amyloidosis covers a diverse collection of diseases that manifest by the extracellular deposition of fibrillar amyloid protein. Amyloid depo sits occur in many tissues (e.g., the skin, kidneys, heart , and brain) as well as in a variety oflocations in the head and neck, including the eye and the major and minor salivary glands. Moreover, submucosal deposits can appear in the nose, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, tracheobronchial tree, and lung.
The most common site of involvement in the upper respiratory tract is the larynx , and the most common sites within the larynx are the false vocal folds.' The larynx can also be the first site of involvement in systemic amyloidosis, although laryng eal involvement is less common in systemic amyloidosis than it is in localized disease.
Amyloidosis localized to the lower respiratory tract is classified according to its bronchoscopic appearanc e as either tracheobronchial or parenchymal? The tracheobronchial pattern is further categorized as either diffus e (more common) or localized (tumor-like masses). The parenchymal pattern is subcategorized as either diffuse or nodular (more common). Although localized amyloid depositions in both the upper and lower respiratory tracts have been reported, this combin ation is very uncommon. "
Our review of the literature reveals that most patients with locali zed laryngotracheobronchial amyloidosis are Caucasian and that most of these cases occur beyond the age of 40 years (table 1) . Initial symptoms typically include hoarseness, cough, and/or dyspnea. The usual upper respiratory (larynge al) location is the supraglottis, while the usual lower respiratory tract pattern is tracheobronchial. Because examination of the subglottis and lower respiratory tract by flexible fiberoptic laryngoscopy is inadequ ate, most patients require direct laryngoscopy and bron choscopy.
Inthe older literature particul arly, amylo id lesions were occasion ally confu sed with tuberculomas and syphilitic gummas ; they have also been mistaken for vocal fold polyps and other benign and malignant tumors . However, most author s agree that these lesions have a fairly typical appearance; they generally appear as sessile, mucosacovered masses with a yellowish waxy surface, as was the case with our patient. 10 Given this characteristic appearance, it is reasonable for the surgeon who is considering this disease in the differential diagno sis to take liberal biopsies ofthese lesion s in a therapeutic effort to decrease the resistance to flow in the airways. Of course , the initial endoscop y is primarily diagnostic, and tissue must be sent for pathologic interpretation. Light micro scopy will demonstrate glass y eosinophilic material in the submucosa and the classic apple-green birefringence on Congo red staining under a polarizing lens. The current classification system for the entire group of amyloid diseases is based on the determination of the subunit protein by immunohistochemical staining (table 2) 12 The 5-year survival rate for these patients is less than 20%; it is even lower among those who have cardiac or renal involvement."
The examination to determine the prese nce of systemic amyloidosis is summarized in table 3. Once the determination is made that the lesion represents localized amyloidosis, certain management conclusions can be drawn from a review of the limited number of cases reported thus far in the literature (table I) .
Management of combined upper and lower respiratory tract amyloidosis is strictly surgical. Although one report described the use of steroids in combination with surgical treatment," most authors agree that neither steroids nor radiation therapy should be used in the management of localized laryngotracheobronchial amyloidosis.P:" In fact, treatments that compromise the immun e response-steroids, immunosuppressive chemotherapeutic agents, and ionizing radia tion-might even accelerate the process."
The goal of treatment is to remove as much of the grossly visible amyloid as possible without sacrificing normal tissue. A complete "oncologic" resection is rarely achieved. Overzealous resection can result in perforat ion of a bronchus or severe hemoptysis." Some reports on management oflaryngotracheobronchial amyloidosis have suggested that there are clinical advantages to the use of CO 2 laser surger y.IS Compared with conventional surgery, laser therapy might be more precise, might cause less inflammation and scarring, and might result in more rapid healing. Rat Hepatocyt eDNA Repair Assay Micron ucleusTest (Mice) DominantLethalTest (Mice) Long-termcarcinogenicitystudies inmice and rats havebeen completed forclprotloxacin. After daily oral doses of 750 mg/l<g (mice) and 250 mg/l<g (rats) were administered for up to2 years, there was noevidencethat ciprofloxacin had anycarcinogenicor tumorigeniceffects in these species. No long termstud-iesofCIPRO' HCOTIC suspension havebeen pertormedto evaluate carcinogenic potential. Fert ili ty studies pertormed in rats at oral doses of ciprofloxacin up to 100 mg/l<glday revealed no evidence of impairment. This would be over 1000 times the maximum recommended clinical dose of ototorical clprotloxacln based uponbody surtace area, assuming total absorption of ciprofloxacin from the ear a apatient treated wit h CIPRO' HCOTIC twice per day. Long ter m studies have not been perf ormed to evaluate the carcinogenic potential or the effect on fertilityoftopical hydrocorti sone. Mutagenicitystudies withhydrocort isonewe renegative. Pregnancy: Teralogenic Effects. Pregnancy Category C: Reproduction studies havebeen pert ormed in rats and miceusing oral doses of up to 100 mg/l<g and IV doses up to 30 mg/l<g and havereveal ed no evidence of har m tothefetus asaresult ofciprofloxaci n. In rabbits, ciprofloxacin (30 and 100mg/l<g orally) produced gastrointestinal disturbances resultinginmaternalweig ht loss and an increasedincidence of abortion, but no teratogenicity was observed ateitherdose. After intravenous administration ofdoses upto 20mg/l<g, no mat ernaltoxicity was producedintherabbit, and no embryotoxicity or ter atogenici tywas observed. Corticosteroids are generally teratogenic in laboratory ani mals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application inlaboratoryanimals. Animal reproducti on studies have not been conducted with CIPRO' HC OTIC. No adequate and well controlled studies have been pertormed in pregnant women. Caution should be exercised when CIPRO' HCOTIC is used byapregnant woman. Nursing Mothers: Ci prolloxacin is excreted in humanmi lk with systemic use. It is notknown whether ciprofloxacin is excreted in human milk following topical oticadministration. Because of the potential for seriousadverse reactionsin nursinginfants, adecision should bemadewhether to discontinue nursing or to discontinue thedrug, taking into account the import anceofthe drug to the mother. Pediatric use: The safety and efficacy of CI PRO' HCOTIC have been establ ished in pediatric patients 2 years and older (131 patients) in adequate and well-controlled clini cal trials. Although no data are available on patients less than age 2 years, there are no known safety concerns or differences in the di seaseprocess inthispopulation which would preclude useof thisproduct inpatients one year and older. See OOSAGE ANO AOMINISTRATION. AOVERSE REACTIONS In Phase 3 clinical trials,a total of564 patients weretreated with CIPRO' HCOTIC. Adverse events with at least remote rel ationship to treatment included headache (1.2%) and pruritus (0.4%). The following treatment-rel ated adverse events were each reported in a si ngle patient: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash , urt icaria, and alopecia. NDC0065-8531-10 CI PRO'isaregisteredtrademarkofBayer AG. Li 
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